Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Influenza C infections in Western Australia and Victoria from 2008 to 2014

Comparison of Influenza C viruses detected from Australian clinical samples with Influenza C viruses detected in other parts of the world in recent years

Research

The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia

This study aimed to determine the vaccine effectiveness of the southern hemisphere trivalent inactivated influenza vaccine (TIV) in preventing...

Research

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

HPV-16/18 AS04-adjuvanted vaccine reduces HPV-16/18 infection and associated cervical endpoints in women regardless of age, location, or sexual experience

Research

Optimization is required when using linked hospital and laboratory data to investigate respiratory infections

Despite a recommendation for microbiological testing, only 45% of children hospitalized for respiratory infections in our previous data linkage study linked...

Research

A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women.

Influenza vaccination during pregnancy can prevent serious illness in expectant mothers and provide protection to newborns...

Research

Human infant memory B cell and CD4+ T cell responses to HibMenCY-TT glyco- conjugate vaccine

Carrier-specific T cell and polysaccharide-specific B cell memory responses are not well characterised in infants following glyco-conjugate vaccination.

Research

A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Research

Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 months

A bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...

Research

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:

Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...

Research

Can linked emergency department data help assess the out-of-hospital burden of acute lower respiratory infections

There is a lack of data on the out-of-hospital burden of acute lower respiratory infections (ALRI) in developed countries.